Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Loteprednol etabonate transmucosal - Alcon

Next Previous
Drug Profile

Loteprednol etabonate transmucosal - Alcon

Alternative Names: 0.25% LE-MPP; 1% LE-MPP; EYSUVIS; INVELTYS; KPI-121; KPI-121 0.25%; KPI-121 1%; LE-MPP; Loteprednol etabonate MPP; Loteprednol etabonate mucus-penetrating particles - KALA BIO; Loteprednol etabonate ophthalmic suspension 0.25% - KALA BIO; Loteprednol etabonate ophthalmic suspension 1% - KALA BIO; MPP-formulated loteprednol etabonate ophthalmic nanosuspension - KALA BIO

Latest Information Update: 04 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kala Pharmaceuticals
  • Developer KALA BIO
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Eye disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes; Ocular inflammation; Ocular pain
  • Phase II Diabetic macular oedema; Meibomianitis; Retinal vein occlusion

Most Recent Events

  • 02 Aug 2023 Kala Pharmaceuticals is now called KALA BIO
  • 11 Jul 2022 Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon
  • 07 Apr 2022 9353933 - No updates
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top